The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid
Gastrinoma, Zollinger Ellison Syndrome
About this trial
This is an interventional treatment trial for Gastrinoma focused on measuring Zollinger-Ellison Syndrome, Gastrinoma, Acid Hypersecretion, H+-K+ ATPase Inhibitor
Eligibility Criteria
INCLUSION CRITERIA: Subjects for receiving oral Omeprazole will be patients who have idiopathic gastric acid hypersecretion with basal rates of gastric acid secretion of greater than 15 mEq/hr and patients with Zollinger-Ellison syndrome with basal acid output greater than 10mEq/hr are eligible. Subjects with gastric acid hypersecretory states who are being treated with various antisecretory drugs under the protocols entitled "Medical Therapy of Zollinger-Ellison Syndrome" (89-DK-0015) are eligible. Patients must be 18 years of age or older. EXCLUSION CRITERIA: Female patients of childbearing age who are attempting to become pregnant, are pregnant, or are unwilling to practice effective birth control will be excluded. Patients who develop adverse reactions or allergic responses to Omeprazole will be excluded.
Sites / Locations
- National Institutes of Health Clinical Center, 9000 Rockville Pike